Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis

被引：0
|
作者：
Bruce Strober
Laura C. Coates
Mark G. Lebwohl
Atul Deodhar
Evan Leibowitz
Katelyn Rowland
Alexa P. Kollmeier
Megan Miller
Yanli Wang
Shu Li
Soumya D. Chakravarty
Daphne Chan
May Shawi
Ya-Wen Yang
Diamant Thaҫi
Proton Rahman
机构：
[1] Yale University,Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
[2] Central Connecticut Dermatology Research,Department of Dermatology
[3] University of Oxford,Division of Arthritis and Rheumatic Diseases
[4] Icahn School of Medicine at Mount Sinai,Immunology Global Medical Affairs
[5] Oregon Health & Science University,Institute and Comprehensive Center for Inflammatory Medicine
[6] Janssen Scientific Affairs,Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine
[7] LLC,undefined
[8] Janssen Research & Development,undefined
[9] LLC,undefined
[10] Janssen Research & Development,undefined
[11] LLC,undefined
[12] Drexel University College of Medicine,undefined
[13] Immunology,undefined
[14] Janssen Research & Development,undefined
[15] LLC,undefined
[16] Janssen Pharmaceutical Companies of Johnson & Johnson,undefined
[17] University of Luebeck,undefined
[18] Memorial University of Newfoundland,undefined
来源：
Drug Safety | 2024年 / 47卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：39 / 57
页数：18
相关论文
共 50 条
  • [1] Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis
    Strober, Bruce
    Coates, Laura C.
    Lebwohl, Mark G.
    Deodhar, Atul
    Leibowitz, Evan
    Rowland, Katelyn
    Kollmeier, Alexa P.
    Miller, Megan
    Wang, Yanli
    Li, Shu
    Chakravarty, Soumya D.
    Chan, Daphne
    Shawi, May
    Yang, Ya-Wen
    Thaci, Diamant
    Rahman, Proton
    DRUG SAFETY, 2024, 47 (01) : 39 - 57
  • [2] SAFETY OF GUSELKUMAB IN PATIENTS WITH PSORIATIC DISEASE: AN INTEGRATED ANALYSIS OF 11 PHASE 2 AND 3 CLINICAL STUDIES IN PSORIASIS AND PSORIATIC ARTHRITIS
    Strober, Bruce
    Coates, Laura
    Yu, Jenny
    Rowland, Katelyn
    Leibowitz, Evan
    Miller, Megan
    Kollmeier, Alexa
    Li, Shu
    Wang, Yanli
    Chan, Daphne
    Chakravarty, Soumya
    Yang, Ya-Wen
    Shawi, May
    Lebwohl, Mark
    Rahman, Proton
    RHEUMATOLOGY, 2023, 62
  • [3] Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of 11 Phase 2/3 Clinical Studies in Psoriasis and Psoriatic Arthritis
    Strober, Bruce
    Coates, Laura
    Yu, Jenny
    Rowland, Katelyn
    Leibowitz, Evan
    Miller, Megan
    Kollmeier, Alexa
    Li, Shu
    Wang, Yanli
    Chan, Daphne
    Chakravarty, Soumya
    Yang, Ya-Wen
    Shawi, May
    Lebwohl, Mark
    Rahman, Proton
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4199 - 4202
  • [4] Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: Integrated Analysis of Psoriasis and Psoriatic Arthritis Clinical Trial Data
    Gordon, Kenneth
    Blauvelt, Andrew
    Bachelez, Herve
    Coates, Laura
    Kaplan, Blair
    Koetse, Willem
    Drogaris, Leonidas
    Sinvhal, Ranjeeta
    Papp, Kim A.
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2791 - 2793
  • [5] Risankizumab Long-Term Safety in Patients With Psoriatic Disease: Integrated Interval Analyses From Psoriasis and Psoriatic Arthritis Clinical Trials
    Gordon, Kenneth
    Blauvelt, Andrew
    Coates, Laura C.
    Kaplan, Blair
    Koetse, Willem
    Drogaris, Leonidas
    Sinvhal, Ranjeeta
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB219 - AB219
  • [6] SAFETY OF GUSELKUMAB ACROSS DIVERSE PATIENT SUBGROUPS WITH PSORIATIC DISEASE: AN INTEGRATED ANALYSIS OF 11 PHASE 2/3 CLINICAL STUDIES IN PSORIASIS AND PSORIATIC ARTHRITIS
    Coates, L.
    Strober, B.
    Yu, J.
    Leibowitz, E.
    Rowland, K.
    Kollmeier, A.
    Miller, M.
    Wang, Y.
    Li, S.
    Chakravarty, S. D.
    Chan, D.
    Shawi, M.
    Yang, Y. W.
    Lebwohl, M.
    Rahman, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1134 - 1135
  • [7] Long-term safety of risankizumab in patients with psoriatic disease: Findings from integrated analyses of 17 clinical trials in psoriasis and 4 in psoriatic arthritis
    Gordon, Kenneth B.
    Blauvelt, Andrew
    Bachelez, Herve
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB78 - AB78
  • [8] LONG-TERM SAFETY OF RISANKIZUMAB IN PATIENTS WITH PSORIATIC DISEASE: FINDINGS FROM INTEGRATED ANALYSES OF 17 CLINICAL TRIALS IN PSORIASIS AND 4 IN PSORIATIC ARTHRITIS
    Gordon, K. B.
    Blauvelt, A.
    Bachelez, H.
    Kaplan, B.
    Koetse, W.
    Drogaris, L.
    Sinvhal, R.
    Papp, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 823 - 823
  • [9] Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
    Subrata Ghosh
    Lianne S. Gensler
    Zijiang Yang
    Chris Gasink
    Soumya D. Chakravarty
    Kamyar Farahi
    Paraneedharan Ramachandran
    Elyssa Ott
    Bruce E. Strober
    Drug Safety, 2019, 42 : 751 - 768
  • [10] Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
    Subrata Ghosh
    Lianne S. Gensler
    Zijiang Yang
    Chris Gasink
    Soumya D. Chakravarty
    Kamyar Farahi
    Paraneedharan Ramachandran
    Elyssa Ott
    Bruce E. Strober
    Drug Safety, 2019, 42 : 809 - 809
12345